CAR-T in Lymphoma
Session VII of iwNHL 2018 saw David Maloney, MD, PhD, James Kochenderfer, MD, Bianca Santomasso, MD, PhD and Stephen Schuster, MD discuss CAR-T cell therapy and associated issues of toxicity and task of commercialization.
Presentations
Fred Hutchinson Cancer Research Center, Seattle, Washington
David Maloney, MD, PhD, from Fred Hutchinson Cancer Research Center, Seattle, Washington, speaks on CD19-directed CAR-T cell therapies.
The National Cancer Institute, Rockville, MD
James Kochenderfer, MD from The National Cancer Institute, Rockville, MD, talks about the management of CAR-T cell therapy-related toxicities.
Memorial Sloan Kettering Cancer Center, New York City, NY
Bianca Santomasso, MD, PhD from Memorial Sloan Kettering Cancer Center, New York City, NY, speaks on neurotoxic events associated with CAR-T cell therapy.
University of Pensylvania, Philadelphia, PA
Steve Schuster, MD, from University of Pennsylvania, Philadelphia, PA, talks about the use of anti-CD19 CAR-T cells in aggressive non-Hodgkin lymphoma,
